Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics.

CPT: Pharmacometrics & Systems Pharmacology
Emmanuel ChigutsaP Kellie Turner

Abstract

Abemaciclib is an oral anticancer drug that inhibits cyclin dependent kinases 4 and 6 and is metabolized by cytochrome P450 3A in the intestines and liver to active metabolites. The objectives were (1) to develop a mechanistic model to characterize the pharmacokinetics (PK) of the active moieties and investigate the effect of patient factors and (2) apply the model to dat from two phase III breast cancer trials of abemaciclib in combination with endocrine therapy. To develop the model, data from seven phase I studies and two phase II studies including 421 patients with cancer and 65 healthy individuals were pooled for nonlinear mixed effects modeling. The PK was similar between patients and healthy subjects, and the effects of diarrhea, formulation, race, and patient covariates on exposure were negligible. Application of the model confirmed its predictive performance and that abemaciclib PK did not change when coadministered with endocrine therapy.

References

Jan 1, 1984·Clinical Pharmacokinetics·S M Pond, T N Tozer
Dec 1, 1995·Journal of Pharmacokinetics and Biopharmaceutics·M O KarlssonL B Sheiner
May 1, 1996·Clinical Pharmacokinetics·N H Holford
Jul 19, 2005·Computer Methods and Programs in Biomedicine·Lars LindbomNiclas Jonsson
Jan 6, 2011·British Journal of Clinical Pharmacology·Stephen B DuffullHelen R Winter
May 24, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maura N DicklerJosé Baselga
Jun 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeAntonio Llombart-Cussac
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzAngelo Di Leo

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01394016
NCT01739309
NCT02014129
NCT01913314
NCT02117648
NCT02256267
NCT02059148
NCT02102490
NCT02327143

Software Mentioned

PsN
NONMEM
OMEGA
JPBM

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.